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Abstract
Objective: Although increasing attention is directed at identifying biological mechanisms underlying
cognitive changes observed in cancer patients without central nervous system disease following che-
motherapy, psychological factors that can contribute to these cognitive changes are much less studied.
Methods: In an online experiment, the influence of informing patients about the association
between cognitive problems and chemotherapy on self‐reported cognitive functioning and neu-
ropsychological test performance was investigated.
Results: Cancer patients treated with chemotherapy (n= 150) reported higher levels of cogni-
tive complaints after receiving such information (M= 21.20) than without such information
(M= 18.98; p= 0.032). No difference was found for patients without (a history of) chemotherapy
(n = 86;M= 18.85 vs. 20.08; NS). A similar interaction pattern was observed on a word‐learning
test. Patients treated with chemotherapy recalled fewer words after being informed about the
association between cognitive problems and chemotherapy (M= 24.44) than without such infor-
mation (M= 27.63; p= 0.010). No difference was found for patients not treated with chemother-
apy (M= 26.35 vs. 25.38; NS).
Conclusion: Patient information may induce a stereotype threat, which affects self‐reported
cognitive function and neuropsychological test performance in cancer patients for whom this in-
formation is relevant.
Copyright © 2011 John Wiley & Sons, Ltd.
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Introduction
Neuropsychological studies show that cognitive
changes may occur in a subset of cancer patients fol-
lowing chemotherapy. Insight into mechanisms that
underlie these cognitive changes improves, but much
needs to be learned. Most current studies are rooted
in biology, unraveling the complex neural basis of
cognitive changes associated with chemotherapy
[1–4]. Less is known about relevant psychological
variables. Although studies show that the reporting
of cognitive complaints by patients is often related
to symptoms of anxiety and depression and to gen-
eral complaints such as fatigue, psychological fac-
tors tend to show only weak associations with
cognitive problems as measured by neuropsycholog-
ical tests [5–7].
A thus far overlooked explanation that can con-
tribute to the occurrence of cognitive problems is
the extent to which a patient is (made) aware of the
possibility of cognitive problems following chemo-
therapy. The proposition that mere awareness about
potential side effects can increase the occurrence of
side effects draws on a large body of evidence from so-
cial psychological and health psychology researches
on the concept of stereotype threat, proposing that
the activation of stereotypical information—such as
‘chemotherapy causes cognitive problems’—can have
a powerful effect on cognitive performance [8,9].
Famous lab studies on prejudice have shown that
informing women that ‘women are bad at math’
lowers their scores on a math test [10]. Likewise,
African Americans primed with racial stereotypes
consistently obtained lower scores on IQ tests [11].
These priming effects are proposed to occur because
negative stereotypes trigger concerns of being evalu-
ated based on this stereotype, which in turn, dis-
rupt performance, thereby creating a self‐fulfilling
prophecy.
Why is this predicament relevant for research on
cognitive problems following chemotherapy? The
effects of stereotypical information may become
stronger with repeated exposure. Hence, mere infor-
mation about chemotherapy‐related side effects, for
Copyright © 2011 John Wiley & Sons, Ltd.
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instance provided by physicians or by patient
groups, may increase cognitive complaints and may
depress cognitive test performance. Recent findings
showed that providing breast cancer patients in a
hospital waiting room with stereotypical information
about the relation between chemotherapy and cogni-
tive problems increased the expression of cognitive
complaints, in particular among patients with prior
awareness of this relation but without chemotherapy
experience [12]. The present study extends these
findings by examining (i) whether priming also
influences actual cognitive performance as assessed
by neuropsychological testing and (ii) whether ste-
reotypical information also functions as a threat
when applied to patients outside the active hospital
setting.
Methods
We applied a 2 × 2 factorial between‐subjects design
in this study. Patients were recruited via cancer web-
sites, where they were asked to participate in an
online study ‘on the effects of cancer therapies on in-
dividual patients’. Following the general opening
text, the participants were randomly assigned—by
computer—to one of two experimental conditions;
half of the patients received the introduction that
‘some patients treated with chemotherapy experi-
ence cognitive problems’ (the priming condition).
The other half of the patients received a neutral intro-
duction (control condition). Self‐reported cogni-
tive complaints were measured with the subscales
‘absent‐mindedness’ and ‘names and words’ of the
Dutch version of the Cognitive Failure Question-
naire [13,14]. These subscales consist of 10 items,
which are rated on a five‐point scale (maximum
score is 40). Higher scores denote more self‐reported
complaints. Cognitive performance was assessed
with the Groningen Fifteen Words Test (short ver-
sion), a learning and memory test commonly used
in the Netherlands, originally developed by Rey
[15,16]. This test was adapted for online use accord-
ing to a procedure developed at Rutgers‐Newark. In
this test, 15 words are successively presented, and
patients are asked to rate each word as positive or
negative. In a subsequent screen, patients are asked
to recall as many words as possible. This procedure
is repeated three times. Correctly recalled words
are summed across trials; higher scores denote
higher levels of cognitive performance (maximum
score is 45). Affect was assessed with five items
from the Positive and Negative Affect Schedule
[17]. The patients had to indicate on a 5‐point Likert
scale the extent to which they experienced a specific
emotion at this moment; higher scores denote more
positive affect. Finally, the patients were asked
whether they had pre‐existing knowledge (prior to
the experiment) about the fact a subgroup of patients
experience cognitive problems during and following
cancer diagnosis and treatment and indicate relevant
medical details, for example, whether they were cur-
rently or previously treated with chemotherapy. The
patients were also asked if they were a member of a
cancer patient organization. The average time to
complete the online experiment was about 20min.
Statistical analyses
The findings were analyzed with the statistical pack-
age SPSS Version 17.0 (SPSS, Inc, Chicago, IL,
USA) using 2 × 2 analyses of variance with primed
introduction (yes, no) and firsthand chemotherapy
experience (yes, no) as between‐subjects factors. As-
sumption of equal variance was assessed with
Levene’s test. Simple effects analyses were used to
further examine significant interaction effects. Effect
sizes were calculated with partial eta square.
Results
A total of 236 cancer patients were included in the
study. Patients who were currently or previously
treated with chemotherapy were assigned to the
‘chemotherapy’ group (n = 150); the remaining
patients were assigned to a group without (a history
of) chemotherapy (n= 86). The experimental and
control groups were equally distributed with regard
to other demographic and clinical variables (Table 1).
Levene’s test confirmed the assumption of equal
variance across conditions. A significant interaction
between priming and firsthand chemotherapy experi-
ence was observed on the Cognitive Failure Ques-
tionnaire (F(1, 232) = 4.01, p= 0.046, ηp
2 = 0.02).
Patients with (a history of) chemotherapy reported
higher levels of cognitive complaints after receiving
a prime (M= 21.20) than without prime (M= 18.98;
p= 0.032). No such difference was found for the
no‐chemotherapy patients (M= 18.85 vs. 20.08, re-
spectively; NS) (Table 2). A similar interaction pat-
tern was observed on the Fifteen Words Test (F(1,
232) = 4.04, p= 0.046, ηp
2 = 0.02). The patients with
chemotherapy learned fewer words after receiving a
prime (M= 24.44) than without prime (M= 27.63;
p= 0.010). No such difference was found for the
no‐chemotherapy patients (M= 26.35 vs. 25.38, re-
spectively; NS) (Table 2). Priming and firsthand
experience with chemotherapy had no effect on af-
fect. Pre‐existing knowledge of the relation between
chemotherapy and cognitive problems had no effect
on self‐reported cognitive complaints and neuropsy-
chological test performance (general knowledge
levels were very high, i.e., most participants knew
about the relationship between chemotherapy and
cognitive complaints; Table 1).
Discussion
Our findings show that mere information about the as-
sociation between cognitive problems and chemother-
apy can increase the reporting of cognitive problems
1133Priming cognitive problems
Copyright © 2011 John Wiley & Sons, Ltd. Psycho-Oncology 21: 1132–1135 (2012)
DOI: 10.1002/pon
and can depress cognitive performance, in particular
for patients who have experience with chemotherapy.
These findings are in line with psychological findings
that stereotype priming predominantly affects cogni-
tive performance of relevant target groups [8–11], al-
though recent evidence suggests that effects on
complaint reporting may extend to other patient
groups [12].
Clearly, more research is needed to identify
groups and group members susceptible to stereotype
priming. Specifically, the relationship among prim-
ing, previous knowledge, and experience with che-
motherapy appears worthwhile examining further.
Although in the present study, priming affected the
reporting of cognitive complaints and cognitive test
scores mainly for patients with a history of chemo-
therapy, a previous study reported opposite findings
on cognitive complaints, that is, that priming in-
creased cognitive complaints mostly for patients
without a history of chemotherapy [12]. It may be
that previous knowledge regarding the relationship
between chemotherapy and cognitive complaints is
a prerequisite for priming effects to occur among
specific target audiences; in the present study,
knowledge levels were very high, whereas in the
previous study, only half of the patients knew about
the relationship between chemotherapy and cogni-
tive complaints. Alternatively, it may be that previ-
ously observed findings were caused by a ceiling
effect. This explanation is corroborated by the fact
that a history of chemotherapy had a main effect on
complaint reporting in the previous study but not in
the present study. Clearly, this issue and other poten-
tial confounds need to be examined further.
One potential limitation of online studies, like the
current study, is that there is no method for confirm-
ing that respondents are actually cancer patients. The
fact that we posted the questionnaire on Internet sites
for cancer patients diminishes this risk considerably.
Nevertheless, future studies should benefit from in-
cluding offline settings to verify patient demograph-
ics and to verify whether participants completed the
cognitive measures on their own, without the use
of cues.
Table 1. Distribution of demographic and clinical characteristics across groups
Control group (no priming condition) N=120 Experimental group (priming condition) N=116 p‐value
Age, mean (SD) 48.3 (10.3) 48.6 (10.2) 0.83
Experience with CT (%) (n/N)a 56.7 (68/120) 70.7 (82/116) 0.03b
Time since diagnose, years (SD) 4.2 (3.2) 4.5 (4.2) 0.58
Member patient group (%) (n/N) 42.0 (47/112) 44.6 (50/112) 0.79
Breast cancer diagnosis (%) (n/N) 62.5 (75/120) 68.1 (79/116) 0.41
Pre‐existing knowledgeb (%) (n/N) 78.4 (91/116) 73.5 (93/113) 0.44
Working
No (%) (n/N) 40.5 (47/116) 34.8 (39/112)
Yes (%) (n/N) 13.8 (16/116) 15.2 (17/112)
Temporarily stopped (%) (n/N) 45.7 (53/116) 50.0 (56/112) 0.68
Gender
Male (%) (n/N) 8.6 (10/116) 11.6 (13/112)
Female (%) (n/N) 91.4 (106/116) 88.4 (99/112) 0.51
Education
Low (%) (n/N) 24.6 (28/114) 30.6 (34/111)
Moderate (%) (n/N) 57.9 (66/114) 57.7 (64/111)
High (%) (n/N) 17.5 (20/114) 11.7 (13/111) 0.36
Variations in N across demographic and patient characteristics due to missing values.
SD, standard deviation; CT, chemotherapy.
aCT, past or current chemotherapy (six patients were currently receiving chemotherapy).
bPre‐existing knowledge on relation between cancer treatment and cognitive problems.
Table 2. Mean scores (standard deviation) of self‐reported cognitive complaints and cognitive performance as a function of experi-
ence with chemotherapy and experimental condition (priming versus no priming)
Experimental group (priming) N= 116 Control group (no priming) N=120 p‐value ηp2
Cognitive complaints (CFQ)
CT a 21.20 (6.4) 18.98 (6.7) 0.032 0.02
No CT 18.85 (6.1) 20.08 (5.3) 0.375 0.003
Cognitive performance (Groningen Fifteen Words Test)
CT a 24.44 (8.3) 27.63 (7.1) 0.010 0.03
No CT 26.35 (6.7) 25.38 (7.3) 0.561 0.001
CFQ, Cognitive Failure Questionnaire; CT, chemotherapy.
aCT, past or current chemotherapy (six patients were currently receiving chemotherapy).
1134 S. B. Schagen et al.
Copyright © 2011 John Wiley & Sons, Ltd. Psycho-Oncology 21: 1132–1135 (2012)
DOI: 10.1002/pon
Our research should be regarded as a first indica-
tion that psychological concepts like stereotype
threat may play a contributory role in the occur-
rence of cognitive problems. Future studies should
examine the duration of this effect and test whether
frequent exposure to stereotypical information in-
creases its impact by inducing chronic activation
of stereotypical information, as may be expected
from related research [8,9]. This is particularly im-
portant considering that public awareness of the rela-
tion between cancer treatment and cognition is
growing [18]. Increased awareness may not only am-
plify the reporting and occurrence of cognitive prob-
lems for groups at risk, it may also amplify patients’
requests for effective interventions. Currently, em-
pirically supported neuropsychological rehabilita-
tion programs for cancer patients are still limited
but increasingly studied [19,20]. Social psycholog-
ical research suggests that teaching target groups
about stereotype threat or providing them with posi-
tive affirmations may attenuate the negative effects
of stereotype threat [21,22]. Mere information may
cause and undo the negative effects of stereotype ac-
tivation. Future studies should not only focus to fur-
ther refine our understanding of the psychological
processes that can hamper cognitive functioning
and on specific risk groups, but also on what can
be done to reduce or prevent the occurrence of cog-
nitive problems from a social psychological point
of view.
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